Bevacizumab and Triamcinolone for Branch Vein Occlusion
Article information
To the Editor
Dear Editor,
I write to you with regard to the article by Kim and Park, titled 'Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion' [1]. Their study compared the effects of standard doses of bevacizumab (1.25 mg) and triamcinolone (4 mg) intravitreally for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). The results in terms of improvements in visual acuity and central macular thickness were similar between those treated with intravitreal bevacizumab (IVB) and those treated with intravitreal triamcinolone (IVT). Despite the seemingly promising results, there are two concerns we would like to address.
First, subjects were given treatment without being given an observation period to allow for spontaneous resolution. The natural history of BRVO can be variable and can resolve without treatment, especially for cases in which perfusion is re-established after the initial attack. In the classic Branch Vein Occlusion Study (BVOS) [2], subjects were observed for spontaneous resolution for at least 12 weeks, and, in the cases in which resolution was unlikely, treatment was offered. In the current study, both IVB and IVT were given without an observation period in whichspontaneous resolution may occur. Although the mean time from diagnosis to injection was more than 12 weeks in both groups, some patients received injection treatment as early as 0 weeks after diagnosis of BRVO (Table 1) [1]. This may only add potential risks to eyes in which spontaneous resolution can occur. Furthermore, this precluded comparison with the BVOS, since the treatment time frames were different.
Next, the only well-established, evidence-based treatment of choice for macular edema secondary to BRVO is grid laser treatment, according to the BVOS [2] and the recent Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study [3]. In the multi-center randomized trial SCORE study, IVT (either 1 mg or 4 mg) failed to produce a superior effect, when compared to that of subjects who received grid laser treatment, and risk of adverse events was highest in the 4 mg-IVT treatment arm. Hence, to date, grid laser treatment remains the benchmark for other new treatment options in comparing effects in eyes with vision loss due to ME from BRVO [3]. That being said, if the authors intend to demonstrate the effectiveness of IVB, comparison with subjects that had grid laser treatment, rather than IVT, is required.
Notes
No potential conflict of interest relevant to this article was reported.